ChiCTR2500115810 版本V1.0 版本创建时间2025/12/31 12:01:26 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500115810 

最近更新日期:

Date of Last Refreshed on:

2025-12-31 12:01:13 

注册时间:

Date of Registration:

2025-12-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

肺癌术后持续性肺漏气群组轨迹风险评估及精准护理干预模式构建与效果评价

Public title:

Group-Based Trajectory Risk Assessment of Postoperative Prolonged Air Leak and Evaluation of a Precision Nursing Intervention Model

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肺癌术后持续性肺漏气群组轨迹风险评估及精准护理干预模式构建与效果评价

Scientific title:

Group-Based Trajectory Risk Assessment of Postoperative Prolonged Air Leak and Evaluation of a Precision Nursing Intervention Model

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

全伊萍 

研究负责人:

全伊萍 

Applicant:

Quan Yiping 

Study leader:

Quan Yiping 

申请注册联系人电话:

Applicant telephone:

+86 10 88128061

研究负责人电话:

Study leader's
telephone:

+86 10 88128061

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1836763015@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1836763015@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市拱墅区半山东路1号

研究负责人通讯地址:

浙江省杭州市拱墅区半山东路1号

Applicant address:

No. 1, Banshan East Road, Gongshu District, Hangzhou City, Zhejiang Province

Study leader's address:

No. 1, Banshan East Road, Gongshu District, Hangzhou City, Zhejiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江省肿瘤医院

Applicant's institution:

Zhejiang Cancer Hospital

研究负责人所在单位:

浙江省肿瘤医院

Affiliation of the Leader:

Zhejiang Cancer Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

IRB-2025-1630(IIT)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江省肿瘤医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Zhejiang Cancer Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-25 00:00:00

伦理委员会联系人:

王丽虹

Contact Name of the ethic committee:

Wang Lihong

伦理委员会联系地址:

浙江省杭州市拱墅区半山东路1号

Contact Address of the ethic committee:

No. 1, Banshan East Road, Gongshu District, Hangzhou City, Zhejiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 88122564

伦理委员会联系人邮箱:

Contact email of the ethic committee:

ec@zjcc.org.cn

研究实施负责(组长)单位:

浙江省肿瘤医院

Primary sponsor:

Zhejiang Cancer Hospital

研究实施负责(组长)单位地址:

浙江省杭州市拱墅区半山东路1号

Primary sponsor's address:

No. 1, Banshan East Road, Gongshu District, Hangzhou City, Zhejiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江省肿瘤医院

具体地址:

浙江省杭州市拱墅区半山东路1号

Institution
hospital:

Zhejiang Cancer Hospital

Address:

No. 1, Banshan East Road, Gongshu District, Hangzhou City, Zhejiang Province

经费或物资来源:

浙江省卫生健康行业科技计划项目

Source(s) of funding:

Zhejiang Provincial Health and Medical Scientific Research Program

研究疾病:

持续性肺漏气  

Target disease:

Persistent lung leakage

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在通过引入群组轨迹模型对肺癌术后持续性肺漏气的动态演变过程进行识别和分层,基于数字化胸腔引流系统获取的实时漏气监测数据,揭示不同患者术后漏气恢复模式的异质性,构建具有临床预测价值的PAL风险分层体系;进一步分析影响各漏气轨迹组归属的术前、术中和术后早期因素,开发可操作的PAL风险预测工具,实现对PAL高危患者的早期识别。在此基础上,结合循证证据与专家共识,制定基于轨迹分层的精准护理干预方案,并通过随机对照试验验证其在降低PAL发生率、缩短胸管留置时间及住院天数、改善患者康复质量等方面的有效性和安全性,最终建立可推广的精准护理管理模式,为提高肺癌术后恢复质量和推动护理管理从标准化向精准化转型提供科学依据和实践框架。  

Objectives of Study:

This study aims to identify and classify the dynamic trajectories of postoperative prolonged air leak in lung cancer patients by applying group-based trajectory modeling, based on real-time air leak monitoring data obtained from a digital chest drainage system. By revealing the heterogeneity of postoperative air leak recovery patterns, a clinically meaningful risk stratification system for PAL will be established. Furthermore, this study will analyze preoperative, intraoperative, and early postoperative factors associated with different trajectory subgroups to develop a practical PAL risk prediction tool, enabling early identification of high-risk patients. On this basis, a precision nursing intervention model tailored to trajectory-based risk levels will be developed through evidence synthesis and expert consensus. Its effectiveness and safety in reducing PAL incidence, shortening chest tube duration and hospital length of stay, and improving postoperative recovery quality will be evaluated through a randomized controlled trial. Ultimately, this study seeks to establish a scalable precision nursing management model to enhance postoperative recovery in lung cancer patients and promote the transition of clinical nursing management from standardized to precision-based approaches.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、年龄 18–80岁,性别不限; 2、原发性肺癌 经组织病理学确诊或高度疑诊; 3、计划行择期肺叶切除术(单叶或双叶;开胸或胸腔镜均可); 4、术后预期连接数字化胸腔引流系统(队列阶段要求胸管留置>=24h); 5、术前心肺功能评估可耐受手术; 6、患者或法定代理人签署知情同意书; 7、能配合护理干预实施与随访。

Inclusion criteria

1.Age: 18-80 years old, gender not limited. 2. Primary lung cancer is confirmed by histopathology or highly suspected. 3. Plan to undergo elective lobectomy (single or double lobectomy; thoracotomy or thoracoscopy are both acceptable); 4. It is expected that the digital thoracic drainage system will be connected after the operation (the thoracic tube should be left in place for more than 24 hours during the cohort stage). 5. Preoperative cardiopulmonary function assessment shows that the patient can tolerate the surgery. 6. The patient or their legal representative signs the informed consent form; 7. Be able to cooperate with the implementation of nursing intervention and follow-up.

排除标准:

1、既往同侧胸部手术史或胸膜疾病史; 2、术前合并活动性胸腔感染/脓胸或大量胸腔积液; 3、术中发现广泛胸膜播散需改为姑息手术; 4、合并严重认知障碍/精神疾病/沟通障碍,无法配合; 5、预期生存期<3个月的终末期患者(RCT阶段口径); 6、同时参加其他临床试验; 7、研究者判断不适合入组的其他情况; 8.(队列阶段补充)围手术期死亡(术后30天内)或关键变量缺失>50% / 设备故障致数据无法获取。

Exclusion criteria:

1. Previous history of ipsilateral chest surgery or pleural diseases; 2. Preoperative active thoracic infection/empyema or a large amount of pleural effusion; 3. Extensive pleural dissemination was found during the operation, and it needs to be changed to palliative surgery. 4. Combined with severe cognitive impairment/mental illness/communication disorders, unable to cooperate; 5. End-stage patients with an expected survival period of less than 3 months (measured in the RCT stage); 6. Participate in other clinical trials simultaneously; 7. Other circumstances where the researcher determines that enrollment is not suitable; 8. (Supplementary in the cohort stage) Perioperative death (within 30 days after surgery) or absence of key variables >50% / equipment failure resulting in data inability to obtain.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00

干预措施:

Interventions:

组别:

精准护理组

样本量:

225

Group:

Precision Nursing Group

Sample size:

干预措施:

轨迹分层精准护理干预

干预措施代码:

Intervention:

Trajectory-based Precision Nursing Intervention

Intervention code:

组别:

常规护理组

样本量:

225

Group:

Usual Care Group

Sample size:

干预措施:

常规围术期护理

干预措施代码:

Intervention:

Standard Perioperative Nursing Care

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Zhejiang Cancer Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后持续性肺漏气发生率

指标类型:

主要指标

Outcome:

Incidence of Prolonged Air Leak

Type:

Primary indicator

测量时间点:

术后第5天及出院前最终胸腔引流评估时

测量方法:

通过数字化胸腔引流系统记录漏气情况,结合胸外科医师与护理记录确认持续漏气≥5天者定义为PAL。

Measure time point of outcome:

Postoperative day 5 and before discharge

Measure method:

Digital chest drainage system monitoring combined with clinical documentation; PAL defined as air leak persisting ≥5 days postoperatively.

指标中文名:

住院总天数

指标类型:

次要指标

Outcome:

Total length of hospital stay

Type:

Secondary indicator

测量时间点:

出院时

测量方法:

医院信息系统调取

Measure time point of outcome:

At discharge

Measure method:

Hospital electronic medical record system (days)

指标中文名:

肺复张情况

指标类型:

次要指标

Outcome:

Lung Re-expansion

Type:

Secondary indicator

测量时间点:

拔胸管前

测量方法:

床旁胸片评估(以拔管前一次影像为准

Measure time point of outcome:

Immediately before chest tube removal

Measure method:

Bedside chest X-ray assessment before tube removal

指标中文名:

术后疼痛评分

指标类型:

次要指标

Outcome:

Postoperative pain score

Type:

Secondary indicator

测量时间点:

术后每日

测量方法:

数字疼痛评分量

Measure time point of outcome:

Daily postoperatively

Measure method:

Numerical Rating Scale for Pain

指标中文名:

胸管留置时间

指标类型:

次要指标

Outcome:

Duration of Chest Tube Placement

Type:

Secondary indicator

测量时间点:

住院期间每日记录,直至拔管

测量方法:

通过护理文书记录查询

Measure time point of outcome:

Record daily throughout the hospitalization until the chest tube is removed.

Measure method:

Recorded from nursing documentation

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机分组序列由未参与研究实施的独立第三方人员使用计算机随机数表法生成

Randomization Procedure (please state who generates the random number sequence and by what method):

The random grouping sequence was generated by independent third-party personnel who were not involved in the research implementation using the computer random number table method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

开放标签,对评估者隐藏分组

Blinding:

Open-label study with blinded-evaluators

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF;EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF;EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-12-31 12:01:13